LRG1 and colorectal carcinoma: Since many agents that target individual nodes of the IL-6/STAT3/LRG-1 cascade, including IL-6, IL-6R, or JAKs/STAT3, are currently under active investigations as treatments for hematopoietic malignancies and solid tumors, this work opens a new and implementable way to mitigate metastasis by blocking CAF-tumor cell crosstalk in CRC[24].